Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

alcon laboratories, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), sodium acetate (unii: 4550k0sc9b) (sodium cation - unii:lyr4m0nh37), sodium citrate (unii: 1q73q2julr) (sodium cation - unii:lyr4m0nh37) - sodium chloride 6.4 mg in 1 ml - for use as an extraocular and intraocular irrigating solution during ocular surgical procedure involving perfusion of the eye with an expected maximum duration of less than 60 minutes.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

alcon laboratories, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), sodium acetate (unii: 4550k0sc9b) (sodium cation - unii:lyr4m0nh37), sodium citrate (unii: 1q73q2julr) (sodium cation - unii:lyr4m0nh37) - sodium chloride 6.4 mg in 1 ml - for use as an extraocular and intraocular irrigating solution during ocular surgical procedure involving perfusion of the eye with an expected maximum duration of less than 60 minutes.

Կանադա - անգլերեն - Health Canada

vetcom 1979 inc. - vitamin a; vitamin d3; dl-alpha tocopheryl acetate; vitamin b12; folic acid; calcium d-pantothenate; menadione sodium bisulfite; nicotinamide; vitamin b2; choline bitartrate; sodium chloride; potassium chloride; magnesium citrate; calcium gluconate; sodium citrate - powder for solution - 1280000unit; 1000000unit; 1500unit; 2.56mg; 150mg; 3.2g; 500mg; 6.72g; 1.28g; 5.76g; 39.4g; 5.4g; 6.5g; 15.5g; 33.2g - vitamin a 1280000unit; vitamin d3 1000000unit; dl-alpha tocopheryl acetate 1500unit; vitamin b12 2.56mg; folic acid 150mg; calcium d-pantothenate 3.2g; menadione sodium bisulfite 500mg; nicotinamide 6.72g; vitamin b2 1.28g; choline bitartrate 5.76g; sodium chloride 39.4g; potassium chloride 5.4g; magnesium citrate 6.5g; calcium gluconate 15.5g; sodium citrate 33.2g - birds; cattle; horses; poultry; poultry; sheep; swine (pigs)

Կանադա - անգլերեն - Health Canada

interprovincial co-op ltd - vitamin e (dl-alpha tocopheryl acetate); vitamin b12; folic acid; calcium d-pantothenate; menadione; nicotinamide; vitamin b2; choline bitartrate; sodium chloride; potassium chloride; magnesium citrate; calcium gluconate; sodium citrate; vitamin d3; vitamin a - powder - 1500unit; 2.56mg; 150mg; 3.2g; 500mg; 6.72g; 1.28g; 5.76g; 39.4g; 5.4g; 6.5g; 15.5g; 33.2g; 1000000unit; 1280000unit - vitamin e (dl-alpha tocopheryl acetate) 1500unit; vitamin b12 2.56mg; folic acid 150mg; calcium d-pantothenate 3.2g; menadione 500mg; nicotinamide 6.72g; vitamin b2 1.28g; choline bitartrate 5.76g; sodium chloride 39.4g; potassium chloride 5.4g; magnesium citrate 6.5g; calcium gluconate 15.5g; sodium citrate 33.2g; vitamin d3 1000000unit; vitamin a 1280000unit - cattle; horses; poultry; poultry; swine (pigs)

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary the normal potassium ion content of human milk is about 13 meq per liter. since potassium from oral supplements such as potassium chloride extended-release tablets becomes part of the body potassium pool, as long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. safety and effectiveness of potassium chloride extended-release tablets in children have not been established. clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. doses of potassium in patients with cirrhosis produce a larger increase in potassium levels compared to the response in normal patients. based on published literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load. patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently. patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. patients with impaired renal function, particularly if the patient is on raas inhibitors or nsaids, should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia [see drug interactions (7.2,7.3)] . the serum potassium level should be monitored frequently. renal function should be assessed periodically.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary the normal potassium ion content of h

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

advagen pharma ltd - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of human mi

Կանադա - անգլերեն - Health Canada

vetoquinol n a inc - potassium acetate; sodium citrate; dextrose; sodium acetate; sodium chloride; calcium chloride; magnesium chloride - solution - 1.0mg; 0.8mg; 50.0mg; 5.0mg; 5.5mg; 0.3mg; 0.3mg - potassium acetate 1.0mg; sodium citrate 0.8mg; dextrose 50.0mg; sodium acetate 5.0mg; sodium chloride 5.5mg; calcium chloride 0.3mg; magnesium chloride 0.3mg - horses

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

bluepoint laboratories - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride) (see overdosage ). controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. potassium supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of potassium chloride (see precautions: information for patients , and dosage and administration sections). all solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients ha